Article ; Online: A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients.
International journal of cancer
2024 Volume 154, Issue 10, Page(s) 1794–1801
Abstract: ... 102 (Arm B) on a 28-day cycle. Between January 15, 2016 and October 24, 2018, 104 pts were randomized ... at four international sites, with 96 pts undergoing treatment, 62 in Arm A and 34 in Arm B. Median overall ... survival was 7.15 months for Arm A and 7.66 months for Arm B (HR 0.93, 95% CI: 0.58-1.47, P = .75 ...
Abstract | DNA methyltransferase inhibitors (DNMTi) have demonstrated benefit in reversing resistance to systemic therapies for several cancer types. In a phase II trial of guadecitabine and irinotecan compared to regorafenib or TAS-102 in pts with advanced mCRC refractory to irinotecan. Patients with mCRC refractory to irinotecan were randomized 2:1 to guadecitabine and irinotecan (Arm A) vs standard of care regorafenib or TAS-102 (Arm B) on a 28-day cycle. Between January 15, 2016 and October 24, 2018, 104 pts were randomized at four international sites, with 96 pts undergoing treatment, 62 in Arm A and 34 in Arm B. Median overall survival was 7.15 months for Arm A and 7.66 months for Arm B (HR 0.93, 95% CI: 0.58-1.47, P = .75). The Kaplan-Meier rates of progression free survival at 4 months were 32% in Arm A and 26% in Arm B. Common ≥Grade 3 treatment related adverse events in Arm A were neutropenia (42%), anemia (18%), diarrhea (11%), compared to Arm B pts with neutropenia (12%), anemia (12%). Guadecitabine and irinotecan had similar OS compared to standard of care TAS-102 or regorafenib, with evidence of target modulation. Clinical trial information: NCT01896856. |
---|---|
MeSH term(s) | Humans ; Irinotecan/therapeutic use ; Colorectal Neoplasms/pathology ; Treatment Outcome ; Colonic Neoplasms/drug therapy ; Rectal Neoplasms/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Neutropenia ; Anemia/drug therapy ; Thymine ; Trifluridine ; Azacitidine/analogs & derivatives ; Phenylurea Compounds ; Drug Combinations ; Pyrrolidines ; Pyridines |
Chemical Substances | Irinotecan (7673326042) ; trifluridine tipiracil drug combination ; guadecitabine (2KT4YN1DP7) ; regorafenib (24T2A1DOYB) ; Thymine (QR26YLT7LT) ; Trifluridine (RMW9V5RW38) ; Azacitidine (M801H13NRU) ; Phenylurea Compounds ; Drug Combinations ; Pyrrolidines ; Pyridines |
Language | English |
Publishing date | 2024-02-05 |
Publishing country | United States |
Document type | Randomized Controlled Trial ; Clinical Trial, Phase II ; Journal Article |
ZDB-ID | 218257-9 |
ISSN | 1097-0215 ; 0020-7136 |
ISSN (online) | 1097-0215 |
ISSN | 0020-7136 |
DOI | 10.1002/ijc.34845 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 478: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 576: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.